For research use only. Not for therapeutic Use.
GNE-6893 is a potent and orally active HPK1 inhibitor. GNE-6893 can be used in research of cancer[1].
| Catalog Number | I041309 |
| CAS Number | 2415374-98-8 |
| Synonyms | [(3R,4S)-4-methyloxolan-3-yl] N-[8-amino-7-fluoro-6-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)isoquinolin-3-yl]carbamate |
| Molecular Formula | C23H24FN5O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H24FN5O4/c1-11-9-31-10-17(11)33-23(30)29-18-6-13-5-14(19(24)20(25)16(13)8-27-18)15-7-28-22-21(12(15)2)26-3-4-32-22/h5-8,11,17,26H,3-4,9-10,25H2,1-2H3,(H,27,29,30)/t11-,17-/m0/s1 |
| InChIKey | ABFKLHVMHUGOBS-GTNSWQLSSA-N |
| SMILES | CC1COCC1OC(=O)NC2=CC3=CC(=C(C(=C3C=N2)N)F)C4=CN=C5C(=C4C)NCCO5 |
| Reference | [1]. Andreas S, et, al. A Convergent Synthesis of HPK1 Inhibitor GNE-6893 via Palladium-Catalyzed Functionalization of a Tetrasubstituted Isoquinoline. Org. Process Res. Dev. 2023;27(3):523-9. |
